Dabur Pharma has signed a supply and distribution agreement with Combino Pharm, one of Spain's leading generic companies, to distribute and market generic oncology products in the Spanish market. The Spanish generic market is currently one of the fastest growing in the world. As per IMS, March 2006, the value of the Spanish generic market was approximately US$ 750 million, with an annual growth rate of 25 per cent.

While the Dabur shall be responsible for registration and supply of products, Combino Pharm will handle the distribution, marketing and sales aspects. The company, which already has approvals for three products in the UK, said that it expects to begin shipping the products to the Spanish market shortly and is awaiting MRP (Mutual Recognition Procedure) approval for its products from the Spanish Regulatory Authority.

Speaking on the occasion Ajay Kumar Vij, CEO of the Dabur Pharma said that "Both companies expect to benefit significantly from each other's strengths and the partnership should enable both to establish a significant presence in the Spanish oncology market".